Risk of metastatic disease on
Cohort Studies
Gallium Isotopes
Gallium Radioisotopes
Humans
Kallikreins
/ blood
Lymphatic Metastasis
Male
Membrane Glycoproteins
Neoplasm Metastasis
Neoplasm Staging
/ methods
Organometallic Compounds
Positron Emission Tomography Computed Tomography
/ methods
Prostate
/ diagnostic imaging
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms
/ diagnostic imaging
Radiopharmaceuticals
Retrospective Studies
#PCSM
#ProstateCancer
PET PSMA scan
primary staging
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
pubmed:
30
5
2019
medline:
19
5
2020
entrez:
30
5
2019
Statut:
ppublish
Résumé
To determine the number of men with A retrospective review conducted on 1253 consecutive men referred by urologists or radiation oncologists to our tertiary referral centre for The median PSA level was 6.5 ng/mL and median ISUP grade was 3, with high-risk disease in 49.7%. The prostate primary was PSMA avid in 91.7% of men. Metastatic disease was identified in 12.1% of men, including 8.2% with a PSA level of <10 ng/mL and 43% with a PSA level of >20 ng/mL. Metastases were identified in 6.4% with ISUP grade 2-3 and 21% with ISUP grade 4-5. Pre-biopsy mpMRI identified metastasis in 8.1% of T2 disease, increasing to 42.4% of T3b. Lymph node metastases were suspected in 107 men, with 47.7% outside the boundaries of an extended pelvic lymph node dissection. Skeletal metastases were identified in 4.7%. In men with intermediate-risk prostate cancer, metastases were identified in 5.2%, compared to 19.9% with high-risk disease. These results support the use of
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Membrane Glycoproteins
0
Organometallic Compounds
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
KLK3 protein, human
EC 3.4.21.-
Kallikreins
EC 3.4.21.-
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-407Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.
Références
Afshar-Oromieh A, Holland-Letz T, Giesel FL et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 2017; 44: 1258-68
Meredith G, Wong D, Yaxley J et al. The use of (68) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 2016; 118 (Suppl. 3): 49-55
Corfield J, Perera M, Bolton D, Lawrentschuk N. (68)Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review. World J Urol 2018; 36: 519-27
Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29
Hicks RJ, Murphy DG, Williams SG. Seduction by sensitivity: reality, illusion, or delusion? The challenge of assessing outcomes after PSMA imaging selection of patients for treatment. J Nucl Med 2017; 58: 1969-71
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-39
Perera M, Papa N, Roberts M et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 2019 [Epub ahead of print]. https://doi.org/10.1016/j.eururo.2019.01.049.
Maurer T, Paehr L, Souvatzoglou M, et al. Preoperative lymph node staging in intermediate to highrisk prostate cancer patients using 68Ga-HBED-PSMA PET hybrid imaging-a patient- and field-based analysis. J Urol 2015;193, E707.
Yaxley J, Raveenthiran S, Nouhaud F et al. Outcomes of primary lymph node staging of prostate cancer with 68Ga-PET/CT PSMA scanning in intermediate and high risk prostate cancer, compared to histological correlation of pelvic lymph node pathology. Can a pre-operative 68Ga-PET/CT PSMA scan replace a PLND for prostate cancer staging? J Urol 2019; 201: 815-20
Swanson GP, Thompson IM, Basler J. Current status of lymph node-positive prostate cancer: incidence and predictors of outcome. Cancer 2006; 107: 439-50
Maurer T, Gschwend JE, Rauscher I et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 2016; 195: 1436-43
von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. (68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 2018; 4: 686-93
Hruby G, Eade T, Emmett L et al. (68) Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer. Asia Pac J Clin Oncol 2018; 14: 343-6
Siriwardana A, Thompson J, van Leeuwen PJ et al. Initial multicentre experience of 68gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. BJU Int 2017; 120: 673-81
van Leeuwen PJ, Emmett L, Ho B et al. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. BJU Int 2017; 119: 209-15
Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 2018; 36: 15-20
Ozgur BC, Gultekin S, Ekici M, Yilmazer D, Alper M. A narrowing range of bone scan in newly diagnosed prostate cancer patients: a retrospective comparative study. Urol Ann 2015; 7: 193-8
Pyka T, Okamoto S, Dahlbender M et al. Comparison of bone scintigraphy and Ga-68-PSMA PET for skeletal staging in prostate cancer. Eur J Nucl Med Mol Imaging 2016; 43: 2114-21
Tanaka N, Fujimoto K, Shinkai T et al. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of ≤20 ng/ml and Gleason score of ≤6 at the initial stage of diagnosis. Jpn J Clin Oncol 2011; 41: 1209-13
Falchook AD, Salloum RG, Hendrix LH, Chen RC. Use of bone scan during initial prostate cancer workup, downstream procedures, and associated Medicare costs. Int J Radiat Oncol Biol Phys 2014; 89: 243-8
Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004; 171 (6 Pt 1): 2122-7
McEwan L, McBean R, Yaxley J, Wong D. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer. J Med Imaging Radiat Oncol 2019; 63: 318-23.